Abstract: A multi-target kinase inhibitor is shown in formula (I), in which R is selected from formula (a), formula (b), formula (c), formula (d), formula (e) and formula (f). The multi-target kinase inhibitor can effectively inhibit the enzymatic activities of RET, VEGFR3 and PDGFRA, and can effectively treat diseases that are regulated and controlled by multi-target kinases and are related to abnormal signal transduction pathways of the multi-target kinases, including cancers of breast, respiratory tract, brain, reproductive organ, digestive tract, urinary tract, eye, liver, skin, head and/or neck and distant metastatic cancers thereof, and lymphoma, sarcoma, leukemia and the like. The active ingredients of the pharmaceutical composition of the present invention comprise a multi-target kinase inhibitor, which accounts for 1-50 wt % of the composition.

Abstract: A reagent for detecting piR-hsa-120522 in plasma is used in the preparation of a non-small cell lung cancer screening or diagnosis kit. Compared with benign nodules and healthy people, piR-hsa-120522 has a significantly higher expression level in plasma of patients with non-small cell lung cancer and precancerous lesions (P<0.05), which indicates that the purpose of screening or diagnosing patients with non-small cell lung cancer can be achieved by means of detecting the expression level of piR-hsa-120522 in plasma.